text:
Tours & Tickets - Volendam, Zaanse Schans e campagna olandese (Small Group Tour)
Fabulous windmills, a number of historic villages and postcard beauty of the Dutch countryside form the ingredients of this smallgroup excursion. Zaanse Schans is famous for its historical atmosphere, authentic warehouses and windmills. You are invited by the miller to enter one of the still working windmills, a fascinating experience! The vibrant fishing village of Volendam has a lively and busy harbor. You can still feel the traditional fishermen's atmosphere on the "Dijk" in the centre of Volendam. There will be enough time for a meal and a visit to the Old Dutch Bakery and the Volendam Museum. At the museum you will get to see traditional costumes, interiors and paintings of Volendam. At the local cheese factory, you will learn everything there is to know about cheese and see how it is made.
Click on the website link for current information regarding the duration and departure times of the tour.

subset: commoncrawl


text:
SOUTH BEND Â? The number dismays Dr. Roland W. Chamblee Sr.:
Forty-two percent of all babies born in St. Joseph County last year were to unwed mothers.
If anyone has a right to speak up, itÂ?s Chamblee. HeÂ?s the countyÂ?s health officer and has been a physician for nearly 50 years.
He sees the community he loves growing worse because of the phenomenon, not better.
Â?We are looking at large numbers of women who are utterly unprepared to be mothers and children sired by men who are utterly unprepared to be fathers,Â? he said.
Â?We are looking at a social catastrophe,Â? he said. Â?We are collaborating in a system that produces massive suffering for millions of children.Â?
Chamblee says you see pregnant girls in your schools, your places of employment and your churches.
For the next several days, The Tribune will examine the truths and fables about the issue.
For more on this story, see SundayÂ?s Tribune.


text:
On this page
Nominate a contact
Employer contact
We write to employers to keep them up to date with what tasks they need to complete and by when.
If your client chooses to be the only point of contact, they must use the nominate a contact form to ensure we have their correct email and address.
Additional contact
If someone else (eg a member of the employer's staff or you acting as their adviser) will be carrying out day-to-day tasks of managing automatic enrolment:
- you (or your client) can confirm that you are the additional contact and provide the correct contact details
- we'll send the additional contact help and guidance by email
What letters are sent to my clients from TPR?
The Pensions Regulator (TPR) sends out letters and emails to employers to support them with their automatic enrolment duties. These letters form a series of communications which are sent to your clients during the automatic enrolment process, helping them to understand their duties and guiding them through what to do next.
You may find it useful to familiarise yourself with these, to help your clients understand what do to and by when.
Related content
Raising your client's staff awareness about automatic enrolment
Your clients' staff will probably want to know how automatic enrolment applies to them.


text: Hi, I am curious if there is an amp (combo or head) that functions well for bass as well as guitar. I enjoy playing Fender Strats, Gibson SG's, and my old Fender Jazz bass, but the amount of equipment needed makes for double case of GAS. I have heard that older Fender Bassman heads perform this dual function well, but I have not experimented with it yet. My thought is it would be a matter of switching cabinets from a 2x12 to a 1x15 (for guitar to bass). As I comb through Ebay I say "Well, there's a good Boogie Mk III, but then there is the Portaflex I saw a few minutes ago..." Your suggestions and ideas would be helpful. Cheers,


text:
Petals Master v1.0, the first official version of the Petals governance tool has been finally released on OW2 today. Here is the quick release note from the Team :
Petals Master 1.0, includes a lot of improvements for users, as well as optimisations, and nice new features :
- Categorize your services, endpoints and enterprises with UDDI based categories or add your own categorization value sets
- Community capabilities : Share ratings, tags and comments on registered services and endpoints with all users
- Share additional information about services by uploading related documents. Supported related document types are: DOC, PDF, XML, HTML, XLS, PPT, TXT, RTF, ODT, ODS, ODP
- Identify your Enterprises with UDDI based identification system (Thomas Register, Dun and Bradstreet (DUNS)), or add your own identification system)
- Search registered entities with a UDDI V2/V3 compliant Inquiry WS API
- Do all what you can do with Petals Master UI with the Petals Master specific WS API
- SLA Management is disabled, but will be back soon, with lots of improvements: SLA enforcement, service contract creation and management based on information collected on execution environments
- Integration with new Petals ESB v3.0 Camelia edition: Govern services and endpoints deployed in Petals ESB by just providing Petals ESB specific WS address and click « synchronize ». That's all !
As mentioned, this tool is integrated with Petals ESB v3.x, so now you can govern services from your Entreprise Service Bus.
There are also several new tools which are connected to Petals ESB, I think that more news will come soon…


text:
BOSTON -- Male circumcision cuts the risk of genital ulcer disease, but not herpes simplex-2, a researcher said here.
The finding comes from a randomized controlled trial in Kisumu, Kenya, one of the three trials that found that circumcision protects against HIV infection in heterosexual men, according to Supriya Mehta, PhD, of the University of Illinois Chicago.
All three studies also looked at possible co-factors of HIV infection, including genital ulcers and herpes infection, Mehta reported at the annual Conference on Retroviruses and Opportunistic Infections.
But they came up with slightly different answers, she noted.
In the other two studies -- conducted in Rakai, Uganda, and Orange Farm, South Africa -- circumcision did protect against herpes infection, Mehta said, and in Rakai it also cut the risk of genital ulcer disease.
Mehta and colleagues found that the efficacy of circumcision against HIV wasn't affected by baseline or incident herpes or genital ulcers -- in contrast to Rakai but consistent with results from Orange Farm.
One possible explanation of the herpes finding might be the high prevalence of the disease in Kisumu, which might have made it difficult to see a small protective effect, Mehta told MedPage Today.
But an outside expert told MedPage Today disparate results on the co-factors don't alter the soundness of the main result -- that male circumcision protects men against catching HIV.
"It's one of the most robust results in the area of HIV protection," according to David Thomas, MD, of Johns Hopkins University in Baltimore, who was not part of the study but who moderated a press conference at which it was presented.
The Kisumu trial, like the others, found that circumcision reduces the risk of HIV by about 60%, Mehta said, but the exact mechanism has not been established.
She and colleagues assessed the protective effect of circumcision against herpes and genital ulcer disease, as well as the impact on HIV, adjusted for the other two conditions.
After adjustment, analysis showed that the circumcised men had a relative risk for HIV, compared with the control group, of 0.39, with a 95% confidence interval from 0.17 to 0.77, Mehta reported.
In other words, she said, the HIV benefit wasn't affected by herpes or genital ulcers, regardless if they were present at baseline or acquired during the study.
The analysis also showed that circumcised men were less likely to acquire genital ulcer disease. The incidence rate ratio was 0.52, with a 95% confidence interval from 0.37 to 0.73.
The protection against genital ulcers was present regardless of whether men had herpes at baseline, acquired the disease during the trial, or never caught herpes, she reported.
On the other hand, there was no protection against herpes, Mehta reported. The incidence rate ratio was 0.94, with a 95% confidence interval from 0.70 to 1.25.
Interestingly, less than a third of the genital ulcers detected during the study were caused by herpes, and 41% had an unknown cause, she reported.
The study was supported by the National Institute of Allergy and Infectious Diseases and the Canadian Institutes of Health Research. Mehta did not report any conflicts.
Reviewed by
Zalman S. Agus, MD Emeritus Professor
University of Pennsylvania School of Medicine and Dorothy Caputo, MA, RN, BC-ADM, CDE, Nurse Planner
Primary Source
Conference on Retroviruses and Opportunistic InfectionsSource Reference: Mehta S, et al "MMC is not protective against HSV-2 incidence but halves the risk of GUD incidence: Results from the randomized trial of MMC to reduce HIV in Kisumu, Kenya" CROI 2011; Abstract 147LB.


text:
The man behind all the fights
One the most awaited movies of February, Sohail Khan's Fight Club promises to be one punch packed entertainer. The film stars major actors like Suniel Shetty, Riteish Deshmukh, Dino Morea, Zayed Khan and Sohail Khan himself to name a few. But one name you might have heard or rather not heard of will be of debutant director Vicky Chopra.
So let us give you a little profile of Mr. Chopra himself.
Chopra started out as a small time actor and has done miniscule roles in a number of films like Vidhu Vinod Chopra's Kareeb and Mission Kashmir, Shyam Benegal's Hari Bhari and Tanuja Chandra's Sangharsh.
According to him, he always wanted to direct films but acted because he wanted to go through the physical upheavals that actors go though during shoots.
And what about producer Sohail Khan? Apparently, both of them are good buddies and wanted to work on a film, years back but nothing materialized. But Sohail kept true to his word and produced Fight Club.
According to Chopra, it is a romantic action film and the title of the film should not turn anyone off and definitely mislead people of what they should expect from the film. Says the confident director that a film with a title like Family does not pull in the audience. It all depends on the film and its content.
And was the man disappointed due to the postponement of the film because of Rang De Basanti? Well, all we can say is that he is hopeful that the RDB craze will die down by the time the film releases on February 17.


text:
Get tips on how to streamline your Logic Pro audio projects Music Production Guru Danny J Lewis.
In this video Danny J. Lewis explores methods within Logic Pro of achieving more space efficient Logic Pro audio projects.
Whether you are transferring re-mix project stems to another computer, submitting tracks for mixdown or simply trying to work a more efficient use of your hard drive space, cleaning up audio projects has many benefits as well as the obvious. What visually appears to be 'dead' audio space may in fact contain harmful frequencies and harmonics which can in turn adversely affect your mix. This is especially true of microphone recordings, where the ambiance of the vocal booth can soon add up with layered vocals to create an underlying hum at often un-audiable frequencies which can easily muddy up a bass part or damage your stereo field.
Danny J. Lewis is an established recording artist and reached high acclaim with his single 'Spend The Night', which hit club chart at No.1 and the national Top 30. Danny's music has been supported by the likes of Masters at Work, Gilles Peterson, David Morales, Kenny Carpenter, Todd Edwards, Todd Terry, and Danny Rampling and more. He's recorded for Defected, Ministry Of Sound, Afroart Records, XL Recordings and others. Danny is currently signed to 4th Floor/Defected Records and runs his own record label, Enzyme Black Recordings.
Danny has also developed an impressive career as a Music Production educator, playing a lead role in the quality and success at Point Blank London and pioneering new approaches to music tech education in online education.
To see and hear more work from Danny check out the following links:
FB Profile: http://www.facebook.com/dannyjlewispage
Youtube Channel: http://www.youtube.com/user/musicprotutorials?feature=watch
Ruff Trx Label: http://rufftrx.tumblr.com/


text:
Many Mid-Atlantic and Northeastern states, buried last week under two feet of snow from the Blizzard of '03, are looking to divert funds allocated for road construction and maintenance to cover snow removal costs.
According to The Washington Post, the Commonwealth of Virginia hopes to shift $63 million from the $2.2 billion in gas and sales taxes earmarked for the state transportation fund.
The State of Maryland, which is facing $20 million in snow cleanup costs, wants to divert up to $300 million from its $2 billion transportation fund both to cover the cost of snow removal.
Under Maryland's plan, road construction would not be affected, but 63 road maintenance programs would be put on hold and local governments would lose $204 million in state funding for transportation projects.
New York governor George Pataki has declared New York City and 14 other counties disaster areas so they can request federal funding to help defray snow and ice cleanup costs. New York mayor Michael Bloomberg said that the city spent $20 million to remove the snow and ice from its roads last week.
New York state's legislature is also debating a bill that would allow local municipalities to issue snow bonds to defray the cost of snow removal over a five year period without cutting into its current budgets.


text:
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
Bloomberg Law: Privacy & Data Security brings you single-source access to the expertise of Bloomberg Law's privacy and data security editorial team, contributing practitioners,...
Sept. 29 — Japan's Ministry of Economy, Trade and Industry (METI) will amend its guidelines implementing the Personal Information Protection Law, Minister Yuko Obuchi said Sept. 26 as she announced enforcement action against a company that faced the largest data breach in Japan.
The announcement came a day after Benesse Holdings Inc. released an independent investigation report concluding that the breach affected 48.6 million of its customers, more than twice the number of affected customers the company previously reported.
The company, which sells correspondence education programs for schoolchildren, initially reported July 9 that 20.7 million customers were affected (136 Privacy Law Watch, 7/16/14)(13 PVLR 1288, 7/21/14). On July 16, the company increased that number to 22.6 million customers (143 Privacy Law Watch, 7/25/14)(13 PVLR 1332, 7/28/14).
Obuchi didn't comment on the details of planned amendments to the METI's data protection guidelines, but she said the changes would reinforce provisions related to data breaches and cybersecurity. She said the guidelines would be amended in 2015.
Obuchi told reporters that METI instructed Benesse that it should reinforce its management structure to prevent the recurrence of the lax data security that allowed a former employee to download the personal information of customers and then transfer it to third parties.
METI said Benesse's lax data security safeguards and poor personal information management violated Article 20 of the Personal Information Protection Law.
Benesse also violated Article 22 of the statute by providing inadequate supervision of personnel, according to a METI spokesman.
Obuchi said that as a result of confirming the violations her ministry was issuing an administrative recommendation to Benesse's management to take measures for better protection of customer private information.
The recommendation included advising Benesse to take responsibility for the actions of its business partners.
The enforcement recommendation focused on the need for the company to reinforce its management attention to data security and ensure that its data protection administrative structure is in place, the METI spokesman said.
The enforcement action didn't include fines or other penalties.
METI's recommendations to Benesse are similar to those made in the independent investigation report released by the company.
That report said the company should :
In addition, the company should clarify its organizational responsibility for protecting personal information, the report said.
To contact the reporter on this story: Toshio Aritake in Tokyo at firstname.lastname@example.com
To contact the editor responsible for this story: Donald G. Aplin at firstname.lastname@example.com
Full text of Benesse's breach report is available, in Japanese, at http://op.bna.com/pl.nsf/r?Open=dapn-9pfm7e.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA's book division. As soon as a new supplement or edition is published (usually annually) for a title you've previously purchased and requested to be placed on standing order, we'll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It's as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you're relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)


text:
Going to the City Hall via public transportation?
The City Hall (Stadshuset) is situated on the island Kungsholmen in the centre of Stockholm.
Buses nr 3 and 53 stop right in front of the City Hall at Hantverkargatan 1. The bus stop is called Stadshuset.
The closest metro station is Rådhuset (the blue line). It takes about 8 minutes to walk to the City Hall from the Central Station, and 5 minutes from the stop Rådhuset.
The closest visitor's parking is on Norr Mälarstrand which also has parking for buses. Parking for the disabled is located at Ragnar Östbergs plan 1-5 on the west side of the City Hall.
There is no wheelchair ramp at the main entrance at Hantverkargatan 1, however there is a ramp located at the large staircase in the middle of the Courtyard. Please notify us by phone if you need to use the ramp and we will assist you. During the tours, it is possible to access the different floors via lifts. Baby strollers and prams may be brought into the City Hall. There is one staircase with 39 steps during the guided tour.
The possibility to sit during guided tours is limited. Chairs are not available, but we have a wheelchair that may be borrowed upon request.
For both public and private tours, hearing loops are available (for up to 38 people). Please contact us before your visit.
Food and drink
You may not bring food and drinks into the City Hall, but feel free to bring something to eat in the Beautiful City Hall Garden
You can also have lunch or a coffee at Ragnars Skafferi, entrance from the court yard. Opening hours: Monday-Friday 07.30-16.00. For more information, please contact Ragnars Skafferi at: +46 (0)8- 586 218 42.
The lavatories in the City Hall are open to all participating in the guided tours. One of the lavatories is adapted for the disabled and may also be used as a nursery room. During certain hours, lavatories reached from the Courtyard, are open to tour participants and the public.
Storage lockers are not available in the City Hall.
Before the start of the tour you may hang your outerwear in our cloakroom. Please note that the cloakrooms are unattended and you should not leave valuables.
Mobile phones
Out of consideration to other visitors and personnel working in the City Hall, please turn off your mobile phones during the guided tour.
City Hall contacts
Visitors' department
Phone: +46 8 508 290 58
E-mail: email@example.com
Event Unit
E-mail: email@example.com
Postal address: City Hall, (reference), SE-105 35 Stockholm


text: FOR IMMEDIATE RELEASE Contact: Matt Rhodes (202) 289-3132 Maine Contact: Greg Dugal – MEIA (207) 865-6100 LODGING INDUSTRY EMPHASIZES VALUE OF SEASONAL WORKERS H-2B seasonal worker program crucial to economic viability of hotels resorts Washington D.C. – June 7 2013 – Sarah Diment owner of The Beachmere Inn in Ogunquit Maine and a member of the American Hotel & Lodging Association (AH&LA) will testify next Wednesday June 12 at a hearing of the House Small Business Subcommittee on Economic Growth Tax and Capital Access in Washington D.C. The hearing "The Seasonal Employment Needs of Small Tourism Businesses and H-2B Visa Policy" has been convened by Subcommittee Chairman Tom Rice (R-SC) to examine the importance of the H-2B visa program and its use by small tourism and tourism-related businesses including hotels and resorts. Diment was invited by the subcommittee to testify on behalf of the lodging industry. "A strong temporary seasonal worker program is vital to the continued strength of hotels inns and resorts across the country many of which generate much of their annual revenue during peak tourist seasons" said Katherine Lugar AH&LA president and CEO. "We are grateful to Chairman Rice for calling this hearing and providing the opportunity to explain to the subcommittee the importance of this program and why its continuation is crucial to our members' economic viability." Created in 1990 the H-2B visa program of the Immigration and Nationality Act allows a maximum of 66000 short-term international workers to fill temporary jobs when no other workers can be found. An employer's participation in the program is contingent on approval by four government agencies and they must also prove that the business has a need for temporary workers extensive recruitment for workers was unsuccessful and the position offers no less than the federal prevailing wage. "Maine is a state of seasonal businesses and none more prominent than those in the state's tourism and specifically lodging industry" said Greg Dugal executive director Maine Innkeepers Association. "In many cases our most desirable destinations are in our least populated areas making it difficult to find the appropriate number of employees as each season rolls around. The H-2B visa program has been an invaluable resource for us to fill this seasonal need and quite frankly I am not sure what we would do without it." In January 2011 the Department of Labor (DOL) issued a rule creating a new prevailing wage methodology for H-2B workers that would have artificially inflated labor costs. Because the rule would harm seasonal businesses throughout the country and put the jobs of full-time workers in jeopardy Congress blocked the rule from going into effect. In May 2013 DOL and the Department of Homeland Security (DHS) reissued essentially the same rule despite the resulting economic harm and the action taken by Congress against the previous rule. Although DOL and DHS deemed that the rule went into effect upon publication comments are being accepted until June 10 2013. # # # Serving the hospitality industry for more than a century the American Hotel & Lodging Association (AH&LA) is the sole national association representing all sectors and stakeholders in the lodging industry including individual hotel property members hotel companies student and faculty members and industry suppliers. Headquartered in Washington D.C. AH&LA provides members with national advocacy on Capitol Hill public relations and image management education research and information and other value-added services to provide bottom-line savings and ensure a positive business climate for the lodging industry. Partner state associations provide local representation and additional cost-saving benefits to members. Matt Rhodes | Director of Marketing/Communications | American Hotel & Lodging Association | 1201 New York Avenue NW Suite 600 Washington DC 20005 | Phone: 202.289.3132 | Fax: 202.289.3128 | email@example.com | www.ahla.com | The leading voice of the lodging industry for more than 100 years.


text:
Halloween Nougat
Time needed
Serving Size / Yield
- 2 C. sugar, plus 5 oz. for egg whites
- 1/4 C. water
- 1/2 C. light corn syrup or agave nectar
- 2 egg whites, at room temperature
- 1 tsp. rose syrup
- 1 tsp. pure vanilla extract
- 1 C. dried apricots, quartered
- 1/2 C. dried cherries, cut bite size
- 1 1/2 C. bittersweet chocolate, chopped fine and melted
- candy thermometer
Our Readers Also Loved
Spray an 8 x 8-inch square baking pan with cooking spray. Line the bottom and sides of the pan with waxed or parchment paper. To make it easier to lift, let the wax paper hang over the sides giving yourself a lip of few inches. Lightly spray the waxed paper inside the pan.
In a heavy bottom saucepan, combine the sugar, water, and corn syrup over low heat. Do not stir- swirl the syrup and sugar until the sugar dissolves. Bring to a simmer, and cook until the syrup turns a nice amber color and the candy thermometer reaches 300 to 310 degrees, about 18 to 20 minutes. This when your syrup is at the hard crack stage. When the syrup registers about 240 degrees.
In a standing mixer fitted with the whisk attachment, start whisking egg whites and a pinch of salt on medium speed until a soft peak develops. Slowly add 2 1/2 ounces of sugar, the vanilla extract, and rose syrup. Continue to whisk the egg whites, on medium speed adding the remaining 2 1/2 ounces of sugar until they are hard peaks and shiny- be careful not to overmix, otherwise the meringue becomes dried and breaks. With the mixer running on low speed, slowly pour in a steady stream of the syrup into the egg whites. Be careful not to let the syrup touch the whisk, pouring down the side of the bowl. Increase the speed to medium-high and continue mixing for 8 minutes until the mixture holds it's shape and is thick.
Using a spatula, sprayed with cooking spray, fold the dried fruit. It will be sticky. Pour the nougat onto the parchment paper, spray your hands with cooking spray and flatten with sprayed hands. Leave to rest overnight at room temperature.
The next day, in a Bain Marie or a double boiler, melt the bittersweet chocolate over a little simmering water. Temper the chocolate, so it stays shiny and beautiful. Invert the baking pan, peel off the waxed paper, and discard. Cut to desired size pieces, with a pizza cutter (spray the pizza cutter with cooking spray), and dip half in chocolate or drizzle chocolate over the top and add sprinkles (optional). Refrigerate until firm, about 30 minutes.
**Try 1/2 teaspoon of vanilla extract or 1 vanilla bean scraped for seeds only
** Be sure to temper the chocolate


text:
Jen performed Honey Tongue's original song "I Wanna Go" live at Teatro ZinZanni in Return To Paradise. Video of Jen's performance
"We knew there was something special about this song from the minute we wrote it," Honey Tongue singer and pianist Jen Ayers said this week. "That was confirmed when we started to see people's reactions to the song when we played it live. There were folks singing along on the first listen, hopping out of chairs, jumping up and down and asking about it after shows." - Gene Stout, Seattle P-I
"I Wanna Go" in Helly Hansen's Extreme Sports DVD


text:
This Limoblaze produced track comes as the second single, following the first official single "Repping" from his soon to be released project "Last Arena".
On this track, each artiste gets to talk about their personal struggles in ministry. May this track be a blessing to every person out there, artiste and listeners alike, Amen.
Download, listen and enjoy!


text: I have a Motorola V186M (Much Music Edition) cell phone that I want to get rid of. I got a new phone like a year ago when I went onto a monthly plan and this one has just been sitting here, taking up space. I only used it for a couple months, so it's in awesome condition. Here is the info..


text:
The couple's son, David, was born two months before his due date and he had underdeveloped lungs and a staph infection, transferred to him before birth, from his mother. After being born he started showing signs of respiratory problems and was turning blue due to the lack of oxygen.
The Hickmans are both members of a faith-healing church in Oregon that is clouded in controversy. As you'll hear in the video above, its members have an unusually high number of child deaths due to their faith-healing practices.
The appeal the Hickmans made last week was based on their conviction, on the grounds that the prosecution had the burden to prove the couple knew their religious beliefs would cause the death of their child, The New York Daily News reported.
During the couple's 2011 trial, a doctor testified that baby David would have had a "99 percent chance" of surviving had the couple called 911 or a doctor. The baby officially died of staphylococcus pneumonia, which could have been treated.
Mr Hickman said he didn't call 911 because he was praying. The couple never considered taking the baby to the hospital, prosecutors said. Instead, they annointed the sickly baby with oils. Shannon Hickman said that she had no choice but to do as her husband said because of church rules.
The Hickmans' conviction on second-degree manslaughter charges typically requires a mandatory minimum sentence of six years in prison, but because of a religious exemption in state law which hadn't expired in 2011, they may only receive 18 months in prison and a $250,000 fine.
Two other parents from the church were convicted earlier this year for failing to seek medical care for their infant daughter.
She had a growth that could have left her blind in one eye – and they were sentenced to three months in jail.


text:
You Can Never Have Enough Elote
No Comments | Written on February 27, 2017 at 10:45 am , by Elizabeth Pietraszek
Elotes, elotes, elotes. There isn't a single thing to hate about this beautiful snack. You can find it on the street, in your local Mexican restaurant, but it's the best when made at home. Not sure how to make you're first one, then you're going to want to make these Appetizing And Simple Elotes.
Keep reading for the recipe…
Better Recipes | Tags:
amazing mexican food, best elote, elote, grilled corn, mexican corn, mexican food, mexican street food, street food
No Comments | POST YOUR COMMENT


text:
How Fast Food Restaurants Work
How Fast Food Restaurants Work is free HD wallpaper. This wallpaper was upload at January 23, 2019 upload by admin in .You can download it in your computer by clicking resolution image in Download by size:. Don't forget to rate and comment if you interest with this wallpaper.
Description wallpaper for How Fast Food Restaurants Work
- Title: How Fast Food Restaurants Work
- Author:
- Upload:
- Link: https://upload.wikimedia.org/wikipedia/commons/2/2c/HK_PolyU_Hung_Hom_Bay_Campus_4th_floor_HKCC_%E5%A4%A7%E5%AE%B6%E6%A8%82_Cafe_de_Coral_pricelist_13-Mar-2013.jpg
- Tag:
- Category: Uncategorized
- View: 0 View


text:
In Bailey's debut novel, a young necromancer must reign in his "tainted" magic and fight on the side of the righteous.
When Koristad agrees to serve as a proxy lightwielder, protecting the innocent alongside the do-gooders blessed with their goddess' power, he makes it clear that he considers the responsibility onerous and ironic. His status as a necromancer makes him a more likely threat than ally in the eyes of many of his new comrades. But he owes a debt to Gregan, the lightwielder who refused to kill Koristad when it appeared the boy might have let his power over the dead go too far. Koristad teams up, ever-protesting, with novice healer Peril, and the two get themselves into and out of a variety of violent situations. Throughout them all, Koristad balances his disdain for lightwielder piety with a wish neither to fall prey to his potentially self-annihilating magic nor to kill when unnecessary. The story is deliberately episodic; Koristad faces a necromancer from his past, a barbarian, a werewolf and an angry mob before even hearing about the mission that sets up the book's sequel. Most of these adventures also include flashbacks that embellish the world's history or shed light on the kinds of players in it. The result is a well-realized mythology with limited exposition. Venturing into different characters' backgrounds, however, sometimes serves to highlight the deficiencies of our heroes. Peevish Koristad and vapid Peril have a familiar relationship in which she wishes to be rescued more promptly and he refuses to admit more than a stoic tolerance of her. Love is surely soon to follow. Also likely in the next installment: political intrigue among the lightwielders, Koristad's confrontation with his father's killer and more on the identity of the mysterious Wraith, who aids Koristad from beyond the grave.
A scattered but enjoyable romp through creative supernatural history.


text:
Lymphocyte inhibition by antagonism of α4 integrins is a validated therapeutic approach for relapsing multiple sclerosis (RMS).
Investigate the effect of CDP323, an oral α4-integrin inhibitor, on lymphocyte biomarkers in RMS.
Seventy-one RMS subjects aged 18–65 years with Expanded Disability Status Scale scores ≤6.5 were randomized to 28-day treatment with CDP323 100 mg twice daily (bid), 500 mg bid, 1000 mg once daily (qd), 1000 mg bid, or placebo.
Relative to placebo, all dosages of CDP323 significantly decreased the capacity of lymphocytes to bind vascular adhesion molecule-1 (VCAM-1) and the expression of α4-integrin on VCAM-1–binding cells. All but the 100-mg bid dosage significantly increased total lymphocytes and naive B cells, memory B cells, and T cells in peripheral blood compared with placebo, and the dose-response relationship was shown to be linear. Marked increases were also observed in natural killer cells and hematopoietic progenitor cells, but only with the 500-mg bid and 1000-mg bid dosages. There were no significant changes in monocytes. The number of samples for regulator and inflammatory T cells was too small to draw any definitive conclusions.
CDP323 at daily doses of 1000 or 2000 mg induced significant increases in total lymphocyte count and suppressed VCAM-1 binding by reducing unbound very late antigen-4 expression on lymphocytes.
Trial Registration
ClinicalTrials.gov NCT00726648.
Citation: Wolf C, Sidhu J, Otoul C, Morris DL, Cnops J, Taubel J, et al. (2013) Pharmacodynamic Consequences of Administration of VLA-4 Antagonist CDP323 to Multiple Sclerosis Subjects: A Randomized, Double-Blind Phase 1/2 Study. PLoS ONE 8(3): e58438. https://doi.org/10.1371/journal.pone.0058438
Editor: Robyn Klein, Washington University, United States of America
Received: July 6, 2012; Accepted: February 5, 2013; Published: March 5, 2013
Copyright: © 2013 Wolf et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was sponsored by UCB Pharma and Biogen Idec Inc. The funders, in consultation with the authors, were included in discussions relating to study design and provided assistance with data analysis. They had no role in data collection or the decision to publish, and contributions to manuscript preparation were restricted to authors employed by the funders and financing of editorial support provided by Infusion Communications.
Competing interests: This study was funded by UCB Pharma and Biogen Idec, which were jointly developing CDP323 as a potential treatment for multiple sclerosis. Dr. Morris has been an employee of and holds stock in GlaxoSmithKline and is currently employed by and has received stock options from UCB Biosciences Inc. Among my coauthors, Dr. Wolf was a salaried employee of UCB Pharma S.A. during the time the study was conducted and has been a consultant for Novartis and Synthon. Dr. Sidhu was a salaried employee of and received stock in UCB Pharma during the time the study was conducted. Dr. Otoul is an employee of UCB Pharma. Dr. Taubel is employed by Richmond Pharmacology, which received financial remuneration for their clinical involvement in this study. Dr. Bennett was a salaried employee of UCB Biosciences Inc. during the time the study was conducted and is now an independent consultant. Dr. Cnops reports no conflicts of interest. This does not alter the authors' adherence to all of the PLOS ONE policies on sharing data and materials.
Multiple sclerosis (MS) is a chronic, disabling autoimmune disease of the central nervous system (CNS) characterized by inflammation, demyelination, and axonal destruction [1]. Relapsing MS (RMS) has a characteristic pathology of intermittent development of multifocal inflammatory lesions in the brain and spinal cord thought to result from activated lymphocytes breaching the blood-brain barrier [2]–[4]. Inflammatory mediators such as tumor necrosis factor-alpha, which is produced during inflammatory responses, induce vascular endothelial cells to express vascular adhesion molecule-1 (VCAM-1) [5]. The diapedesis of lymphocytes into the CNS is dependent on lymphocyte adhesion to vascular endothelial cells. This adhesion is mediated by the binding of integrins such as very late antigen-4 (VLA-4 or α4β1 integrin), expressed on activated lymphocytes, to VCAM-1 [5]–[8].
Inhibition of lymphocyte trafficking by antagonism of α4 integrins is a validated therapeutic approach for inflammatory diseases such as MS [9]. Clinical studies with natalizumab, a recombinant humanized monoclonal antibody that targets α4β1 integrin, have confirmed that this integrin is an effective therapeutic target for relapsing forms of MS [10]. Through selective inhibition of α4β1 integrin, natalizumab effectively disrupts migration of immune cells and reduces subsequent CNS inflammation [6], [11], [12]. Therapeutically, this results in reduced numbers of inflammatory brain lesions, lower exacerbation rates, and delayed progression of MS disability [10], [12], [13].
Small-molecule α4 antagonists such as CDP323 (UCB Pharma, Brussels, Belgium, and Biogen Idec, Weston, MA, USA), a phenylalanine enamide mixed α4 antagonist [9], have been considered potential alternatives to therapeutic antibodies because of their increased selectivity for specific α4-containing integrin complexes, their inhibition of different affinity states, and the increased patient convenience of oral dosing [14]–[16]. In addition, their short half-lives compared with those of antibodies permits relatively fast elimination from the body in the event of serious side effects that necessitate termination of therapy.
Preclinical investigations have shown that CDP323 possesses anti-inflammatory properties [6], [11], and phase 1 data in human volunteers have suggested that CDP323 is a potent and effective α4 inhibitor that is well tolerated at oral doses up to 1000 mg twice daily (bid) [17]. The 1000-mg bid CDP323 dosage appears to have a similar effect on peripheral lymphocyte counts in healthy subjects as natalizumab does at doses of 3 and 6 mg/kg in subjects with MS [18]. However, no data have been gathered on the effects of CDP323 on peripheral lymphocyte counts. The magnitude of increased total lymphocyte counts induced by an α4 antagonist may be indicative of its potential to inhibit lymphocyte trafficking and, therefore, predictive of its therapeutic potential, though this has not been formally validated.
When the current study was designed, a 24-week serial MRI phase 2 study investigating two dosages of CDP323 in RMS subjects was ongoing [19]. The study reported herein was intended to complement data on the exposure-response relationship (ie, the 24-week study) by using CDP323 in a wider dosage range and examining different lymphocyte subsets over a 4-week period in subjects with RMS. The objectives of the present study were to identify and support a minimally effective dosage of CDP323 in RMS therapy (as assessed by biomarker changes) and to collect additional information on the biomarker effects and safety of a previously unused higher dosage (1000 mg bid).
In addition, this study investigated CDP323 1000 mg given once daily (qd) in order to characterize how a partial recovery of VCAM-1 binding during a 24-hour dosing interval would affect the trafficking of lymphocytes. A working hypothesis was that a partial recovery might offer safety advantages.
This was a hybrid phase 1/phase 2, double-blind, randomized, parallel-group, placebo-controlled study conducted at a single center in London (UK). Male and female subjects aged 18 to 65 years with a diagnosis of RMS, an Expanded Disability Status Scale (EDSS) score of ≤6.5, one relapse within the last 24 months, and no other conditions that could potentially compromise the immune response were recruited to the study. Subjects were excluded if, prior to study screening, they had received immunomodulating or immunosuppressive drugs within 30 days (for interferons, glatiramer acetate, corticosteroids, adrenocorticotropic hormone, or recombinant cytokines), 6 months (for azathioprine, cyclosporine A, or human antibodies), or 12 months (for natalizumab, rituximab, or mitoxantrone); if they had ever been treated with cyclophosphamide; or if they had received total lymphoid irradiation, any antilymphocyte monoclonal antibody therapy, or any inoculation with attenuated live vaccines in the 30 days prior to screening. Subjects were not permitted to take any form of concomitant immunosuppressive or immunomodulatory therapy during the study or for a period of 30 days following completion or withdrawal from the study.
Subjects were randomized to receive placebo or CDP323 at dosages of 100, 500, or 1000 mg qd or 1000 mg bid for a period of 28 consecutive days (day 1 to day 28; last dose given as a morning dose). Treatment was supplied as hard-gelatin capsules containing 50 mg or 250 mg of CDP323 or matched placebo.
Subjects were hospitalized for the first 5 days following initiation of treatment and for the last 2 nights of the treatment period. Pharmacodynamic (PD) assessments were conducted during the predose phase (screening; day −1 at 08∶00, 09∶00, 10∶00, 12∶00, 16∶00, and 20∶00 hours), during the first day of study medication administration (day 1: predose and 1, 2, 4, 8, 12, and 24 hours post-dose), on day 15 (predose), and after the final dose on day 28 (predose and 1, 2, 4, 8, 12, 24, 48, 72, 96, and 168 hours post-dose). Assessments consisted of measurement of absolute counts of total lymphocytes, B cells, T cells, monocytes, hematopoietic progenitor cells, natural killer (NK) cells, NK T cells, regulator T cells (Treg), and inflammatory T cells. Expression of α4 was also recorded for each subset of lymphocytes except for inflammatory T cells. In addition, the effect of CDP323 on VCAM-1 inhibition was investigated as well.
The protocol for this trial and supporting CONSORT checklist are available as supporting information; see Checklist S1 and Protocol S1.
Flow Cytometry Methodology
All samples were analyzed by Esoterix Clinical Trial Services (Mechelen, Belgium). White blood cell and differential white blood cell counts were obtained from each whole blood sample using a hematological analyzer before staining and analysis. A 100-µL sample of sodium heparin anticoagulated whole blood from each patient was mixed with appropriate amounts of fluorescent monoclonal antibody cocktails, CD3 peridinin chlorophyll protein (perCP), or CD19 perCP antibody complex and incubated in the dark for 20 minutes. To each tube, 4 mL of a warm lysing solution was added. Samples were mixed and allowed to stand in the dark for a further 5 minutes. After washing, pellets were fixated with 500 µL of 1% paraformaldehyde. Data were acquired with a FACSCalibur™ (BD Biosciences, Erembodegem, Belgium) and analyzed with CellQuest™ software (BD Biosciences). Fluorescence markers for each subject were optimized to assess nonspecific staining.
Statistical Analysis
Because of the exploratory nature of this study, no formal sample size computation was performed. A sample of 15 subjects per group was considered adequate to describe the effects of CDP323 upon biomarkers across the three tested dosage levels.
Statistical analysis was performed using SAS® software version 9.1 (SAS Institute, Cary, NC, USA). The analysis was performed on the per protocol (PP) population, a subset of subjects without any major protocol deviations affecting the PD evaluation defined prior to database lock and unblinding. Missing values were not imputed. Each leukocyte subset (raw absolute count and percentage change from baseline [defined as measurements collected on day −1]) was analyzed separately and summarized by treatment group and time-point measurements or by day (mean over 24 hours duration) using graphical displays and summary statistics (mean and standard deviation [SD]).
Analyses were conducted for the percentage change from baseline (time-matched day −1) observed at the end of treatment (day 28) in absolute lymphocyte and lymphocyte subset cell counts, VCAM-1 inhibition, and α4 expression. These data were analyzed using a mixed-effect model repeated-measures analysis of variance (ANOVA; PROC MIXED in SAS) with the subject as the random effect, treatment and treatment by time-point interaction as fixed effects, and baseline values as a covariate. The treatment by time-point interaction was inspected. The dose-response relationship (using the dosages of 0, 200 mg/day, 1000 mg/day [as 1000 mg qd or 500 mg bid], or 2000 mg/day) was investigated by means of a linear trend test contrast [20] for unequally spaced doses in the SAS PROC MIXED model with a type-I error of 0.05. (Negative quadratic contrast was added to check for any plateau effect.).
In addition, five pairwise comparisons to the placebo group were evaluated (with the higher dosages emphasized: 1000 mg bid, 1000 mg qd, and 500 mg bid), and the 500-mg bid and 1000-mg qd regimens were also compared (to assess any potential regimen effect). These comparisons were applied using SAS contrasts of the PROC MIXED procedure. To take into account multiple comparisons (five pairwise comparisons), the type I error of 0.05 was adjusted by Bonferroni correction for these pairwise comparisons. Thus, differences were considered statistically significant when P<0.01.
Ethics Statement
The study was approved by the London–Surrey Borders Research Ethics Committee and overseen by an independent safety advisory board (see Acknowledgments for board members). It was conducted in accordance with the ethical principles of the Declaration of Helsinki, the International Conference on Harmonisation Good Clinical Practice guidelines, and UK laws. Written consent was obtained from all subjects. The study was registered at the National Institutes of Health ClinicalTrials.gov website (identifier: NCT00726648).
Subject Baseline Characteristics
A total of 106 subjects were screened, of whom 71 were randomized to treatment. The majority of subjects (97.2%; n = 69) completed the study; one subject in the CDP323 100-mg bid group was lost to follow-up and one subject in the CDP323 500-mg bid group discontinued because of a positive pregnancy test at day 27. The latter subject, who did not receive study drug on day 28, was the only exclusion from the PP population (n = 70). Subject disposition in each of the treatment groups is given in Figure 1.
Baseline demographics and disease characteristics are presented in Table 1. There were no clinically relevant differences between the treatment groups with respect to age, race, body mass index, or EDSS score. Overall, 62% of the subjects were female, although the percentage of female subjects in each group varied from 43% to 80%.
The majority of subjects had a diagnosis of relapsing-remitting MS; a higher percentage of subjects had a diagnosis of relapsing secondary progressive MS in the CDP323 1000-mg qd group (43%) than in the other groups (21% to 29%). The mean annualized relapse rate determined over the 12 months prior to the study was 1.3.
PD Effects of CDP323
Summary data for absolute counts of lymphocytes and lymphocyte subsets at baseline, day 1, and day 28 are presented in Table 2. Table 3 presents the percentage change from baseline, based on absolute counts, in total peripheral blood lymphocytes and lymphocyte subsets following treatment with CDP323 for 28 days.
Dose-response analysis showed a statistically significant linear trend increase for total lymphocytes, naive B cells, memory B cells, T cells, and NK cells. For NK T cells, the significant negative quadratic trend highlighted a rise of the NK T cell count from 0 mg (placebo) to 1000 mg/day (500 mg bid and 1000 mg qd), corresponding to the daily dose at which maximum increase occurred (mean of 43.4%), followed by a decline (28.8%) at 2000 mg/day.
Mean increases in the total lymphocyte count of 43.7% and 46.2% were found with CDP323 dosages of 500 mg bid and 1000 mg bid, respectively. Smaller mean increases were seen with the 1000-mg qd (39.7%) and 100-mg bid (8.1%) dosages as well as in the placebo group (12.1%). Increases in total lymphocytes were statistically significantly greater with all dosages of CDP323 except the lowest (100-mg bid) dosage than with placebo (Table 2). On day 28, the peak percentage of total lymphocytes was generally observed 8 to 12 hours following dosing of CDP323, and it returned to pretreatment baseline values approximately 24 hours after dosing.
Compared with placebo, the 500-mg bid, 1000-mg qd, and 1000-mg bid dosages of CDP323 generally resulted in statistically significant increases in naive B, memory B, and NK cells (Table 3). Increases in NK T cells observed with CDP323 compared with placebo reached statistical significance only with the 500-mg bid dosage. Although the mean percentage increase from baseline in hematopoietic progenitor cells was substantially greater following administration of CDP323 (65.1%–185.7%) compared with placebo (18.6%), the considerable intersubject variability occluded any statistically significant findings for the 100-mg bid and 1000-mg bid dosages. With the exception of the 100-mg bid dosage, CDP323 resulted in increases in monocytes compared with placebo, although none was statistically significant. Similarly, no statistically significant differences were observed for any of the lymphocyte subsets with CDP323 100 mg bid compared with placebo. Results for changes in Treg cells and inflammatory T cells were inconclusive because the number of samples was insufficient for meaningful analysis.
In general, each of the PD parameters assessed returned to predose values within 24 to 96 hours after the last dose of CDP323 on day 28. Figure 2 shows the time profile of geometric mean values for total lymphocytes from all dosage groups.
bid = twice daily; qd = once daily.
Patients in the placebo group showed mean increases in lymphocyte binding to VCAM-1 of 41.7% and expression of α4-integrin on VCAM-1–binding cells of 33.6%, which may be the result of normal variations observed in lymphocyte counts [21]. In contrast, administration of CDP323 (at all dosages) caused statistically significant reductions compared with placebo in lymphocyte binding to VCAM-1 (mean reduction of 81.8%–97.0%; P≤0.003; Figure 3A) and in the expression of α4-integrin on VCAM-1–binding cells (mean reduction of 44.0%–54.6%; P≤0.0001; Figure 3B).
bid = twice daily; CI = confidence interval; qd = once daily; VCAM-1 = vascular adhesion molecule-1.
CDP323 was well tolerated in this study, with headache being the most frequently reported adverse event (AE) across the treatment groups (Table 4). The majority of AEs were mild or moderate in severity, and there were no deaths during the study. Four subjects reported a total of five serious AEs: hypoglycemia (placebo), unintended pregnancy and abortion induced (CDP323 500 mg bid), gamma-glutamyltransferase increase (CDP323 1000 mg bid), and hallucinations mixed (CDP323 1000 mg qd). Only the pregnancy event resulted in discontinuation from the study. Four subjects treated with CDP323 had at least one elevated liver function test of grade 3 or 4 according to the Common Terminology Criteria for Adverse Events (version 3; 9 August 2006). There were no consistent changes in any safety laboratory or vital signs parameters. No cases of opportunistic infection were identified during the study.
This hybrid phase 1/2 study assessed the effect of different dosages of CDP323, a small-molecule α4-integrin antagonist, on changes in total lymphocytes and lymphocyte subsets in subjects with RMS. In general, the numbers of circulating T, B, NK, NK T, and hematopoietic progenitor cells were significantly greater in subjects who had received CDP323 dosages of 1000 mg qd (smallest increases), 500 mg bid, or 1000 mg bid (largest increases) than in those who had received placebo. In total lymphocytes and most subtypes, the dose-response relationship was shown to be linear.
The observed effect of CDP323 on the total peripheral blood lymphocyte count and the number of circulating mature and immature B cells was similar to the effects previously reported with the humanized monoclonal α4β1-integrin antibody natalizumab [22]–[24]. Unlike natalizumab, CDP323 had no significant effect on the number of circulating monocytes [23], nor on Treg and inflammatory T-cell counts. However, the sample size for the Treg and inflammatory T-cell results was too small to permit any definitive conclusions to be drawn.
The PD effects of CDP323 on lymphocytes and lymphocyte subsets are readily reversible, with cell numbers generally returning to predose levels within 96 hours after the last administered dose. However, given the short duration of this study, it is not possible to predict treatment reversibility after long-term CDP323 administration.
Functional inactivation of the α4 integrin has been observed following mobilization of CD34+ hematopoietic stem cells [25], and it is known that these cells are mobilized by natalizumab when it is used in the treatment of patients with MS [26]–[29]. CDP323 appears to have similar effects on these cells and was observed to significantly decrease the capacity of lymphocytes to bind VCAM-1 and α4 integrin on VCAM-1–binding cells compared with placebo.
The differences in the effects of CDP323 and natalizumab on circulating lymphocytes demonstrate that despite targeting the same molecule, albeit via different delivery pathways, these compounds may induce distinct changes in leukocyte production and, possibly, functionality. Though the significance of these findings in relation to α4 antagonism and changes in circulating lymphocyte levels remain unknown, the limited efficacy of CDP323 on brain lesions in a serial MRI phase 2 study [19] as compared with the substantial efficacy of natalizumab may indicate that the stable antagonism achieved by a long-acting antibody has clinical significance.
Supporting Information
Checklist S1.
CONSORT Checklist.
Protocol S1.
Trial Protocol.
The authors thank Ans Valgaeren and Bella Ertik (UCB S.A.) for their expert operational assistance in the analyses of the samples from this study and thank Ralph Bloomfield (UCB Celltech) for independent statistical advice to the safety Advisory Board. Medical writing support was provided by Mark Hughes and editorial support was provided by Joshua Safran, both of Infusion Communications. Independent Safety Advisory Board: Gavin Giovannoni (chair; London, UK), Tarek Yousry (London, UK), Mark Van Ranst (Leuven, Belgium).
Author Contributions
Conceived and designed the experiments: CW JS CO JT. Performed the experiments: JT. Analyzed the data: CW JS CO DLM JC JT BB. Wrote the paper: CW JS CO DLM JC JT BB.
- 1. Stadelmann C, Wegner C, Brück W (2011) Inflammation, demyelination, and degeneration–recent insights from MS pathology. Biochim Biophys Acta 1812: 275–282.
- 2. Ferguson TA, Mizutani H, Kupper TS (1991) Two integrin-binding peptides abrogate T cell-mediated immune responses in vivo. Proc Natl Acad Sci U S A 88: 8072–8076.
- 3. Chan PY, Aruffo A (1993) VLA-4 integrin mediates lymphocyte migration on the inducible endothelial cell ligand VCAM-1 and the extracellular matrix ligand fibronectin. J Biol Chem 268: 24655–24664.
- 4. D'hooghe MB, Nagels G, Bissay V, De Keyser J (2010) Modifiable factors influencing relapses and disability in multiple sclerosis. Mult Scler 16: 773–785.
- 5. Müller WA (2011) Mechanisms of leukocyte transendothelial migration. Annu Rev Pathol 6: 323–344.
- 6. Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, et al. (1992) Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 356: 63–66.
- 7. Soilu-Hanninen M, Roytta M, Salmi A, Salonen R (1997) Therapy with antibody against leukocyte integrin VLA-4 (CD49d) is effective and safe in virus-facilitated experimental allergic encephalomyelitis. J Neuroimmunol 72: 95–105.
- 8. Lee SJ, Benveniste EN (1999) Adhesion molecule expression and regulation on cells of the central nervous system. J Neuroimmunol 98: 77–88.
- 9. Davenport RJ, Munday JR (2007) Alpha4-integrin antagonism–an effective approach for the treatment of inflammatory diseases? Drug Discov Today 12: 569–576.
- 10. Polman CH, O'Connor PW, Havrdová E, Hutchinson M, Kappos L, et al. (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354: 899–910.
- 11. Kent SJ, Karlik SJ, Cannon C, Hines DK, Yednock TA, et al. (1995) A monoclonal antibody to alpha 4 integrin suppresses and reverses active experimental allergic encephalomyelitis. J Neuroimmunol 58: 1–10.
- 12. Rudick RA, Sandrock A (2004) Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS. Expert Rev Neurother 4: 571–580.
- 13. Radue EW, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, et al. (2010) Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis. J Neurol Sci 292: 28–35.
- 14. Muro F, Iimura S, Yoneda Y, Chiba J, Watanabe T, et al. (2008) Identification of 4-[1-[3-chloro-4-[N'-(5-fluoro-2-methylphenyl)ureido]phenylacetyl]-(4S)-fluoro-(2S)-pyrrolidinylmethoxy]benzoic acid as a potent, orally active VLA-4 antagonist. Bioorg Med Chem 16: 9991–10000.
- 15. Kenyon NJ, Liu R, O'Roark EM, Huang W, Peng L, et al. (2009) An alpha4beta1 integrin antagonist decreases airway inflammation in ovalbumin-exposed mice. Eur J Pharmacol 603: 138–146.
- 16. Vanderslice P, Woodside DG, Caivano AR, Decker ER, Munsch CL, et al. (2010) Potent in vivo suppression of inflammation by selectively targeting the high affinity conformation of integrin alpha4beta1. Biochem Biophys Res Commun 400: 619–624.
- 17. Baker M, Shock A, Parton T, Hales P, Parker G (2006) Pharmacokinetic and pharmacodynamic properties of the VLA-4 inhibitor CDP323. Mult Scler 12: S106.
- 18. Miller D, Khan O, Sheremata W, Blumhardt L, Rice G, et al. (2001) Results of a double-blind, randomized, placebo-controlled, phase II trial of Antegren (natalizumab) in subjects with relapsing multiple sclerosis (MS). Mult Scler 7: S16.
- 19.
Polman C, Bowen J, Barkhof F, Bates D, Wynn D, et al. (2010) Double-blind, placebo-controlled, randomized phase II serial MRI, safety and tolerability study of two doses of CDP323 in subjects with relapsing forms of multiple sclerosis over 24 weeks. Presented at the 62nd Annual Meeting of the American Academy of Neurology, Toronto, Canada.
- 20. Kong L, Koch G, Liu T, Wang H (2005) Performance of some multiple testing procedures to compare three doses of a test drug and placebo. Pharmaceut. Statist. 4: 25–35.
- 21. Kovarik JM, Schmouder R, Barilla D, Riviere GJ, Wang Y, et al. (2004) Multiple-dose FTY720: tolerability, pharmacokinetics, and lymphocyte responses in healthy subjects. J Clin Pharmacol 44: 532–537.
- 22. Niino M, Bodner C, Simard ML, Alatab S, Gano D, et al. (2006) Natalizumab effects on immune cell responses in multiple sclerosis. Ann Neurol 59: 748–754.
- 23. Krumbholz M, Meinl I, Kumpfel T, Hohlfeld R, Meinl E (2008) Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis. Neurology 71: 1350–1354.
- 24. Putzki N, Baranwal MK, Tettenborn B, Limmroth V, Kreuzfelder E (2010) Effects of natalizumab on circulating B cells, T regulatory cells and natural killer cells. Eur Neurol 63: 311–317.
- 25. Lichterfeld M, Martin S, Burkly L, Haas R, Kronenwett R (2000) Mobilization of CD34+ haematopoietic stem cells is associated with a functional inactivation of the integrin very late antigen 4. Br J Haematol 110: 71–81.
- 26. Zohren F, Toutzaris D, Klarner V, Hartung HP, Kieseier B, et al. (2008) The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans. Blood 111: 3893–3895.
- 27. Bonig H, Wundes A, Chang KH, Lucas S, Papayannopoulou T (2008) Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab. Blood 111: 3439–3441.
- 28. Jing D, Oelschlaegel U, Ordemann R, Holig K, Ehninger G, et al. (2010) CD49d blockade by natalizumab in patients with multiple sclerosis affects steady-state hematopoiesis and mobilizes progenitors with a distinct phenotype and function. Bone Marrow Transplant 45: 1489–1496.
- 29. Neumann F, Zohren F, Haas R (2009) The role of natalizumab in hematopoietic stem cell mobilization. Expert Opin Biol Ther 9: 1099–1106.


text:
Please view the following links to further your success in biology. We highly recommend that all students majoring in biology schedule a personal advising session with Megan Presland-Academic Advisor and create a plan to achieve your educational goals, by clicking the Make an Appoinment button at the bottom of this page.
General Advising
What Can You Do With A Biology Degree?
General Studying Advice From Dr. Myers
BIO Student Survival Kit (.ppt)
Pre-Professional Advising
Pre-Med Advising
Pre-Dental Advising
Pre-Physical Therapy Program Comparisons (BS, Health Sciences & BA Human Biology)
PA School Requirements
Guaranteed Admissions Agreement - 2010


text:
Ganz CCTV >
Ganz Security Cameras >
Ganz Indoor Dome Cameras >
Ganz Analog Dome Cameras >
Ganz 4000 Series Indoor Dome Cameras > GANZ ZCA-SM400 Service Monitor Cable 4000 Series Domes
Service Monitor cable for the GANZ 4000 series cameras. This cable lets you test the view at the camera with out having to unhook any of the connections. This cable plugs in to the inside of the dome making service and adjustment a breeze.
Bulk CCTV Store
41W195 Railroad Street, Unit A
Pingree Grove, IL 60140


text: Well I currently own a Blackberry Storm. I am looking forward to the release of the Motorola Droid. I have no complaints with the Storm, It is an awesome phone. I am a tech junkie though and the Android platform has been calling to me since it's release. I look forward to participating in the forums and exploring a new phone and operating system


text:
Archives de 4 septembre 2010
A correlation between poverty and religiosity
Here we go again, and this is from Jerry Coyne, linking to a very nice figure from the New York Times. Looks pretty much like the figures I proposed a few weeks ago from different datasets and certainly quite different questionnaires and metrics. The trent persist, the best countries come with atheists, thank you!
I was more concerned about the outliers who spend time behind the Iron Curtain, Charles Blow discuss one particular outlier, the USA.
Coyne goes back to his January's post « Does insecurity promote faith? » where he presented data and analyses that support the idea.
I very much like Coyne's conclusion:
Nevertheless, Rees and Paul may be onto something. And if they're right, even in part, then we atheists have a bigger task than simply trying to dispel the influence of religion on people. For to do that, we may have to work for better and more just societies. But isn't that, in the end, a nobler goal?
Call the guy strident or a dick or whatever else you like, but please keep in mind that he got some simple and wonderful stances.
Larry Arnhart being evil!
And this is not a fancy title as the one he use: « PZ Myers, Creationist« . He must be off his drugs, or something.
The worst part is calling an atheist a creationist, but Arnhart isn't that stupid as to think anybody will take him seriously on that. But he is enough stupid to use the old journalistic trick like, OMG! DARWIN WAS WRONG! Except that he don't want Darwin to be wrong, just to make a sensational title for his blogpost. And that's not even where he's gone really evil. The worst part is :
Myers says that « the science of biology supports a communist world view. »
What Myers wrote (if you don't truncate the phrase, that's it) is :
I find their arguments that the science of biology supports a communist worldview just as convincing as Arnhart's that it supports classical liberalism…which means not very.
Fucking quote mining with the link provided for people who hadn't it handy and too lazy to Google it! That's embarrassing because it's quite stupid and really evil.
I do agree with Arnhart that the pope is a creationist but Arnhart doesn't seem to be able to understand that the very same evolutionary process he praise explains equally every single political and moral and ethical view that was ever invented and that will be invented in the future and he can't apply it in his particular political views. That's partial politically induced blindness IMO and I'm sorry to have confirmation that Arnhart suffers from it. Usually he is a descent guy. Wish him prompt recovery.
PZ already answered.
Angiogenesis but not neurogenesis is critical for normal learning and memory acquisition
Publié par Oldcola dans Angiogenesis, neuroscience le septembre 4, 2010
Angiogenesis but not neurogenesis is critical for normal learning and memory acquisition
Kerr AL, Steuer EL, Pochtarev V, Swain RA.
Neuroscience Article in Press, Accepted Manuscript doi:10.1016/j.neuroscience.2010.08.008
I'm obsessed with angiogenesis and this have to do with my current work. I came to think that EC play a central role in CNS physiology, especially repair. EC lead you to angiogenesis – invariably.
I love this paper and I'm looking forward to read the discussions it
could should must trigger.


text:
April 19 2016 – 80-Year-Old Nigerian Pensioner Dies Of Heart Attack In Jalingo Taraba After Government Omits Name From Pension Payroll
An elderly man identified as 80-year-old Kusuku Martins died of heart attack in Jalingo Taraba yesterday.
The pensioner went to Taraba State Office of the Nigeria Union of Pensioners to lodge a complaint because he didn't receive his pension in the past two months.
On getting to NUP office, he was told that his name has been removed from the list, on his way back around 4pm, the man suddenly collapsed and died instantly by the road side.
His corpse was abandoned on Barde Way near Government House Junction for several hours yesterday.
When contacted, The Chairman of the Nigeria Union of Pensioners, Hassan Abubakar described Kusuku's death as pathetic.


text:
Organizations Plans Relief For Survivors Of Haiti EarthquakeJanuary 13th, 2010 - 9:03 pm ICT by GD
By Meena Kar
Haiti, Jan 13, (THAINDIAN NEWS) The strong earthquake jolts that had shaken Haiti and claimed the life of several people, has completely devastated the region. As per the reports, it has taken a toll on the human civilization that has developed in this area and turned it into a land of ruins. People all over the world have been alarmed by this disaster and several organizations have offered relief to help the people, who have been victimized by this natural calamity.
According to reports, the headquarters of the United Nations in Haiti has been destroyed in the earthquake and several UN staffs were missing. The destruction of the UN headquarters made it difficult for the organization to provide immediate support to the people. Bill Clinton, former US President reported that the entire UN system as well as his office has been constantly monitoring the entire situation to estimate the disaster scale. US State Secretary, Hillary Clinton said that the country would offer complete support to Haiti.
It has been reported that World Bank is preparing a team to the assess damage caused by the earthquake and plan recovery that would help people recover from the loss. As per the reports, the International Red Cross Society as well as other major organizations has planned relief measures for this region. Simon Schorno, the spokesperson of the ICRC stated that they will send relief team for helping the medical units to deal with the casualties and injuries. It has been reported that Taiwan, Venezuela, Mexico, France and Britain have also offered to provide relief for the earthquake affected region.
- Thousands feared dead as massive earthquake destroys Haiti's capital - Jan 13, 2010
- Haiti's capital devastated by powerful earthquake - Jan 13, 2010
- Japan faces fears of n-radiation, more quakes (Lead) - Mar 16, 2011
- Help pours in after Haiti's capital is devastated by powerful earthquake - Jan 13, 2010
- India asks Haiti politicos to exercise restraint - Jan 22, 2011
- Aid for Haiti a priority as 600,000 still live in camps following quake - Oct 06, 2011
- Robust US aid effort on Pak floods could thwart Taliban influence: Experts - Aug 10, 2010
- Bullock donates $1 million to Japan relief fund - Mar 18, 2011
- Earthquake Of 6.0 Magnitude Hits Manila, Creates Panic - Mar 25, 2010
- Haiti Earthquake Relief Work Needs More Medical Aid & Tent - Jan 29, 2010
- Sean Penn's charity receives cash boost from Bill Clinton - Oct 09, 2010
- Haiti Death Toll Ticking Up Every Moment - Jan 16, 2010
- Relief teams helping Haiti's traumatized quake victims - Jan 15, 2010
- Massive earthquake devastates Haiti (Second Lead) - Jan 13, 2010
- Venezuela Provides $100 Million To Earthquake Hit Haiti - Mar 17, 2010
Tags: bill clinton, casualties, disaster, earthquake jolts, haiti, hillary clinton, human civilization, icrc, kar, medical units, meena, natural calamity, red cross society, relief measures, spokesperson, staffs, state secretary, survivors, united nations, world bank


text:
As a companion post to @h-p-saucecraft on bingeing, what artists do you ration? I find that favourite artists with compact catalogues need to be rationed as the ever-present spectre of overlistening and becoming bored with them would turn a win into a loss. Particularly artists who've been with me for a long time. So Kate Bush, The Clash, New Order, The Blue Nile, Kraftwerk and 10,000 Maniacs for example have to be carefully apportioned out. I listened to The Jam so much as a youngster its not so much listening to them anymore as triggering my internal autoplay.
There are other more fecund artists such as The Fall of course for whom this is less of an issue.


text:
December 30, 2016 – Pictures Of Naija Santa Claus Praying Like Muslim Go Viral
Friends, what would you do if Santa came visiting dressed like a Muslim?
Perhaps, it wouldn't make much difference if you see a Muslim Cleric praying in Santa's outfit.
This is exactly what happened when camera recently caught up with a young Muslim devotee praying to his God in Santa Claus costume.
Like the saying goes, Wonders shall never end….